ValuEngine cut shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA) from a hold rating to a sell rating in a research report report published on Thursday, November 9th.
Other equities research analysts have also recently issued research reports about the company. Citigroup Inc. reaffirmed a buy rating and set a $78.00 price target (down previously from $87.00) on shares of Reata Pharmaceuticals in a report on Wednesday, August 23rd. Zacks Investment Research raised shares of Reata Pharmaceuticals from a strong sell rating to a hold rating in a research note on Tuesday, October 24th. Robert W. Baird reiterated a buy rating and issued a $47.00 target price on shares of Reata Pharmaceuticals in a report on Friday, September 1st. Stifel Nicolaus restated a buy rating and set a $50.00 price objective (up previously from $38.00) on shares of Reata Pharmaceuticals in a report on Tuesday, July 25th. Finally, Piper Jaffray Companies upped their target price on shares of Reata Pharmaceuticals from $53.00 to $60.00 and gave the company a buy rating in a research note on Monday, July 24th. Two investment analysts have rated the stock with a sell rating and eight have assigned a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $54.71.
Reata Pharmaceuticals (RETA) opened at $25.05 on Thursday. Reata Pharmaceuticals has a 1 year low of $18.51 and a 1 year high of $40.88. The company has a quick ratio of 3.18, a current ratio of 3.18 and a debt-to-equity ratio of -0.15.
Reata Pharmaceuticals (NASDAQ:RETA) last released its earnings results on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.11). The business had revenue of $12.60 million during the quarter, compared to the consensus estimate of $12.54 million. The business’s revenue was up .0% on a year-over-year basis. research analysts anticipate that Reata Pharmaceuticals will post -1.9 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Reata Pharmaceuticals, Inc. (RETA) Stock Rating Lowered by ValuEngine” was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://baseballnewssource.com/markets/reata-pharmaceuticals-inc-reta-lowered-to-sell-at-valuengine/1769412.html.
In related news, Director James Edward Bass acquired 3,888 shares of the company’s stock in a transaction dated Wednesday, November 15th. The stock was purchased at an average price of $24.02 per share, with a total value of $93,389.76. Following the completion of the purchase, the director now owns 52,089 shares in the company, valued at approximately $1,251,177.78. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. 62.40% of the stock is owned by company insiders.
Several hedge funds have recently bought and sold shares of RETA. Bank of New York Mellon Corp increased its stake in Reata Pharmaceuticals by 18.1% in the 1st quarter. Bank of New York Mellon Corp now owns 22,213 shares of the company’s stock worth $503,000 after acquiring an additional 3,407 shares during the last quarter. FMR LLC lifted its holdings in shares of Reata Pharmaceuticals by 40.6% in the 1st quarter. FMR LLC now owns 237,606 shares of the company’s stock worth $5,382,000 after buying an additional 68,600 shares during the period. Geode Capital Management LLC lifted its stake in shares of Reata Pharmaceuticals by 19.5% during the 1st quarter. Geode Capital Management LLC now owns 63,778 shares of the company’s stock worth $1,444,000 after purchasing an additional 10,397 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in shares of Reata Pharmaceuticals during the 1st quarter worth $559,000. Finally, Russell Investments Group Ltd. purchased a new stake in shares of Reata Pharmaceuticals during the 2nd quarter worth $254,000. 21.88% of the stock is currently owned by hedge funds and other institutional investors.
About Reata Pharmaceuticals
Reata Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing product candidates that modulate the activity of regulatory proteins involved in the biology of mitochondrial function, oxidative stress, and inflammation to address the unmet medical needs of patients with a range of serious or life-threatening diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Reata Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reata Pharmaceuticals Inc. and related companies with our FREE daily email newsletter.